Guide To Lung Cancer: Causes, Screening, Treatment and New Updates
Lung cancer develops when abnormal cells in lung tissue grow uncontrollably. Understanding risk factors, screening, diagnosis, and treatment options can support informed health decisions.
Lung cancer is a disease in which abnormal cells in the lungs grow without normal control. These cells can form a tumor and, in some cases, spread to other parts of the body. The two main categories are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Tobacco exposure is the most important known risk factor, although lung cancer can also occur in people who have never smoked. Other factors may include exposure to secondhand smoke, radon, certain workplace substances, air pollution, previous radiation exposure, family history, and some existing lung conditions.
Common symptoms can include a persistent cough, coughing up blood, chest discomfort, shortness of breath, unexplained weight loss, repeated respiratory infections, or ongoing tiredness. These symptoms can have many other causes, so they do not by themselves confirm lung cancer.
Why Lung Cancer Awareness Matters
Lung cancer remains a major public-health concern. In the United States, it is the leading cause of cancer death and one of the most commonly diagnosed non-skin cancers.
Early detection can be important because lung cancer may not cause noticeable symptoms during its earlier stages. For people at increased risk, screening with low-dose computed tomography (LDCT) can identify suspicious lung abnormalities before symptoms develop.
| Area | Key Information |
|---|---|
| Main types | NSCLC and SCLC |
| Major risk factor | Tobacco smoking |
| Screening method | Low-dose CT for eligible high-risk adults |
| Important testing | Imaging, biopsy and, when appropriate, biomarker testing |
| Treatment approaches | Surgery, radiation, chemotherapy, targeted therapy and immunotherapy |
Treatment planning depends on factors such as cancer type, stage, overall health, tumor characteristics, and specific genetic or molecular changes.
Recent Lung Cancer Updates
Research and treatment development continued rapidly during 2025 and 2026. An important trend has been the increasing role of biomarker testing in advanced NSCLC. Testing can identify molecular changes that may help clinicians determine whether a targeted therapy is appropriate.
On February 26, 2026, the U.S. Food and Drug Administration granted accelerated approval to zongertinib for certain adults with unresectable or metastatic non-squamous NSCLC containing specific HER2 mutations.
On July 22, 2026, the FDA approved zidesamtinib for adults with locally advanced or metastatic ROS1-positive NSCLC who had previously received at least one ROS1-targeted therapy.
On September 9, 2026, the FDA granted accelerated approval to sevabertinib for certain patients with locally advanced or metastatic non-squamous NSCLC involving HER2 activating mutations.
These developments illustrate why modern lung cancer evaluation increasingly considers the molecular characteristics of a tumor rather than relying only on its location and appearance.
Laws, Screening Policies and Government Programs
Screening recommendations differ by country. In the United States, the U.S. Preventive Services Task Force (USPSTF) recommends annual LDCT screening for adults aged 50 to 80 who have a 20 pack-year or greater smoking history and currently smoke or quit within the previous 15 years. Screening is generally discontinued after 15 years without smoking or when a major health condition limits life expectancy or the ability to undergo curative lung surgery.
A pack-year represents smoking an average of one pack of cigarettes per day for one year.
Government health programs and insurance rules can affect eligibility, documentation, screening intervals, and access to diagnostic evaluation. Requirements can change, so individuals should check the current rules applicable to their location.
Tools And Resources For Lung Cancer Information
Useful educational resources include:
- Lung cancer risk-assessment questionnaires
- Pack-year smoking-history calculators
- Low-dose CT screening decision aids
- Cancer staging diagrams
- Pathology and biopsy information guides
- Biomarker-testing education materials
- Questions-to-ask-your-clinician templates
- Medication and appointment tracking tools
- Evidence-based cancer clinical-trial databases
These resources can help people organize information, but they should not replace individualized medical evaluation.
Frequently Asked Questions
What are the main types of lung cancer?
The two major categories are non-small cell lung cancer and small cell lung cancer. NSCLC includes several subtypes, while SCLC generally behaves differently and is treated using different clinical approaches.
Who may qualify for lung cancer screening?
Under current USPSTF guidance in the United States, adults aged 50–80 with at least 20 pack-years of smoking who currently smoke or quit within the past 15 years are recommended for annual LDCT screening.
Can people who never smoked develop lung cancer?
Yes. Although smoking is the leading risk factor, lung cancer can also occur in people who have never smoked. Environmental exposures, family history, and other factors may contribute to risk.
What tests can diagnose lung cancer?
Evaluation may involve imaging such as CT scans, followed by a biopsy when appropriate. Pathology testing can determine the cancer type, while molecular or biomarker testing may identify changes relevant to treatment planning.
Is lung cancer treatable?
Treatment depends on the cancer's type, stage, molecular characteristics, and the person's overall health. Possible approaches include surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, or combinations of these approaches.
Conclusion
Lung cancer is a complex disease with different types, stages, risk factors, and treatment approaches. Tobacco exposure remains a major preventable risk factor, while screening can help identify lung cancer earlier in certain higher-risk adults.
Recent developments in targeted therapies and biomarker testing are continuing to change how some lung cancers are evaluated and treated. Reliable health information, appropriate screening discussions, and professional medical evaluation are important parts of informed decision-making.
Disclaimer: This article is for general educational purposes only. It does not diagnose lung cancer or replace advice from a qualified healthcare professional. Screening and treatment decisions should be based on an individual's medical history and current clinical guidance.
